INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

13th International Conference on Malignant Lymphoma

 

17-20 June 2015 Lugano
Close
N. Poster
Poster title
Applicant name
Status
  7-OT CHRONOS-1: Phase II trial of intravenous PI3K-&945;/-&946; inhibitor copanlisib in patients with relapsed/refractory indolent non-Hodgkins lymphoma Martin Dreyling Received Received
  8-OT Design of a Phase 1/2, open-label, dose-escalation trial of the Toll-like receptor antagonist IMO-8400 in patients with MYD88 L265P-positive diffuse large B-cell lymphoma James Baker Received Received
  9-OT Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial Michael Wang Received Received
  10-OT Efficacy and Safety of Lenalidomide and Rituximab vs Placebo and Rituximab in a Phase 3 Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Rachel Sopko Received Received
  11-OT FIL-VERAL12: phase II randomized study with Rituximab-DHAP /- Bortezomib as induction in young relapsed/refractory Diffuse Large B-cell Lymphoma eligible to transplant. ANNALISA CHIAPPELLA Received Received
  13-OT The Elderly Project by the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Eldelry Patients with Diffuse Large B-Cell Lymphoma. Francesco Merli Received Received
  14-OT CLLR3 A randomized Phase II trial evaluating the chemotherapies FC/ B combined with GA101 followed by GA101 maintenance in relapsed/ refractory CLL Nadine Kutsch Received Received
  151-P T-cell subpopulations quantified by flow cytometry in lymph node cell suspensions identify a group of patients with follicular lymphoma with favorable outcome Laura Magnano Mayer Received Received
  154-P NR4A3 suppresses lymphomagenesis by induction of apoptosis and serves as a drug target for lymphoma therapy Alexander Deutsch Received Received
  157-P Prognostic impact of cell of origin profile in young patients with high risk diffuse large B cell lymphoma: results of the BIO-DLCL04 trial of Fondazione Italiana Linfomi ANNALISA CHIAPPELLA Received Received
  158-P Cell of origin is not associated with survival after DLBCL relapse Umar Farooq Received Received
  159-P Impact on survival of MYC genetic alterations but not MYD88L265P mutation in primary testicular DLBCL Alexandra Valera Received Received
  160-P MYD88 L265P mutations, but not other variants, identify a subgroup of patients with ABC diffuse large B-cell lymphoma, extranodal involvement and poor outcome JORDINA ROVIRA Received Received
  161-P MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma Ting-Xun Lu Received Received
  162-P Analysis of double-hit lymphoma cases by genetic subtype Daniel Landsburg Received Received
  163-P Molecular characterization of diffuse large B-cell lymphoma recurrences: clonal relationship and different modes of tumor evolution Darius Juskevicius Received Received
  164-P Relapsed DLBCLs present frequent copy number variations of genes involved in lymphomagenesis with different pattern between early- and late-relapsed DLBCLs BROSÉUS Julien Received Received
  166-P Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma Kurt Bantilan Received Received
  168-P PRIMA-1Met induces myeloma and mantle cell lymphoma cell death, by impairing ROS/GSH balance. Benoit Tessoulin Received Received
  169-P Chronic Lymphocytic Leukemia B-cells are rescued from apoptosis by extracellular vesicles from bone marrow mesenchymal stromal cells Emerence Crompot Received Received
  170-P Prognostic significance of TET and IDH mRNA expression in chronic lymphocytic leukemia Michal Van Damme Received Received
  171-P Optimal Treatment Strategies for Early-Stage Hodgkins Lymphoma with B Symptoms and Bulky Disease at Presentation Jay Reddy Received Received
  172-P Infradiaphragmatic Hodgkin Lymphoma: long term outcome improved by chemotherapy-radiotherapy VS chemotherapy alone. cédric rossi Received Received
  173-P Consolidation radiation after ABVD is effective treatment for ed patients with Hodgkins lymphoma (HL) with interim PET positive scans. Noelle ORourke Received Received
  174-P Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data Katerina Dedeckova Received Received
  175-P Cardiac Radiation Dose and Predicted Cardiac Mortality in the UK RAPID Trial in Early Stage Hodgkin Lymphoma David Cutter Received Received
  176-P Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free time points and survival comparison to the general population in British Columbia. Greg Hapgood Received Received
  177-P Healthcare utilization in the AETHERA trial: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post ASCT vijayveer bonthapally Received Received
  179-P Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder (HL-PTLD): A Comparative Analysis of Prognosis and Survival Andrew Evens Received Received
  181-P First in-patient proof of safety and efficacy of a 4th generation chimeric antigen receptor-modified T cells for the treatment of R/R CD30-positive lymphoma Zhitao Ying Received Received
  182-P Chronic lymphocytic leukaemia treatment and outcome in the UKs population-based Haematological Malignancy Research Network Russell Patmore Received Received
  183-P Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B-CLL cells and FCGR3A polymorphism. A study of FCGCLL/MW and GOELAMS groups. Anne-laure Gagez Received Received
  184-P Results of a Phase II randomizing intensified rituximab pre-phase followed by standard FCR vs standard FCR in previously untreated patients with Active B-CLL. Stephane Lepretre Received Received
  185-P A Randomised Study of F(C)R in Fit, Elderly Patients with Chronic Lymphocytic Leukaemia (CLL) shows high response rates and a dose intensity effect Stephen Mulligan Received Received
  186-P Targeting Mutated BRAF with Vemurafenib is Safe and Highly Active in Relapsed/Refractory Hairy Cell Leukemia: a Phase-2 Italian Clinical Trial (HCL-PG01) Enrico Tiacci Received Received
  187-P The clinical course of patients with follicular lymphoma in the rituximab era inas el-najjar Received Received
  188-P Event-free Survival at 12 Months and Subsequent Overall Survival in Patients with Follicular Lymphoma Managed in the Rituximab Era Emmanuel Bachy Received Received
  189-P Follicular lymphoma and clinical characteristics of histologic transformation Miriam Mendez Received Received
  190-P RISK INCIDENCE OF FOLLICULAR LYMPHOMA TRANSFORMATION: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GELTAMO GROUP Sara Alonso-Alvarez Received Received
  191-P Comparison of lenalidomide and rituximab with chemoimmunotherapy in patients with untreated grade 1-2 follicular lymphoma treated at the MD Anderson Cancer Center Chan Yoon Cheah Received Received
  192-P Extended Dosing Lenalidomide with Intensified Rituximab in Untreated Indolent NHL Nathan Fowler Received Received
  196-P Rituximab Maintenance (MR) improves PFS and OS in all Patients (pts) with Follicular Lymphoma (FL) - Individual Patient Data (IPD) meta-analysis Liat Vidal-Fisher Received Received
  199-P Higher risk of rituximab intolerance in patients with Waldenstrm Macroglobulinemia Jorge Castillo Received Received
  201-P Outcomes in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease patients treated with rituximab and liposomal doxorubicin (R-Dox) Thomas Uldrick Received Received
  202-P Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP vs R-CHOP in the phase 3 LYM-3002 study Gregor Verhoef Received Received
  204-P Clinical, metabolic and molecular responses with sequential R-CHOP, high-dose cytarabine, and iodine-131 tositumomab-based transplant in Mantle Cell Lymphoma Kurt Bantilan Received Received
  205-P Multi-center phase II study with lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: survival update and health-related quality-of-life analysis Jia Ruan Received Received
  207-P Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma Peter Martin Received Received
  209-P High Dose Sequential Chemotherapy with Rituximab and ASCT as First Line Therapy in Adult MCL Patients: Clinical and Molecular Response of the MCL0208 Trial, a FIL Study. Sergio Cortelazzo Received Received
  210-P The standard, revised and a simplified International Prognostic Index reliably predict outcome in patients with PET/CT-staged DLBCL treated with R-CHOP Diego Villa Received Received
  211-P Female patients with DLBCL and involvement of the reproductive organs have poor outcomes and markedly increased risk of CNS relapse with R-CHOP(-like) therapy Tarec Christoffer El-Galaly Received Received
  212-P Evaluation of the site of central nervous system (CNS) relapse in patients with Diffuse Large B-cell lymphoma (DLBCL) by the CNS risk model Roopesh Kansara Received Received
  213-P Clinical and Treatment-Related Features Determining the Risk of Late Relapse in Patients with Diffuse Large B-cell Lymphoma Lena Modvig Received Received
  215-P Spleen involvement identified on baseline PET imaging influences outcome of young patients with high risk diffuse large B cell lymphoma treated with R-CHOP14 but not R-ACVBP Olivier Casasnovas Received Received
  217-P Vincristine omission, but not dose reduction, is associated with decreased survival in elderly DLBCL patients Salma Afifi Received Received
  218-P Outcome analysis of diffuse large B cell lymphoma (DLBCL) in HIV-infected and immunocompetent (IC) patients: The Swiss HIV Cohort study (SHCS) Annarita Conconi Received Received
  219-P Secondary CNS lymphoma in the rituximab-era: Data on the first 100 patients from a prospective registry Stephan Kreher Received Received
  220-P Dose-Dense Chemoimmunotherapy and Early CNS Prophylaxis for High-Risk DLBCL Interim Results from a Nordic Phase II Study Sirpa Lepp Received Received
  221-P Systemic high-dose methotrexate (HD-MTX) consolidation in poor-risk diffuse large B-cell lymphoma is associated with improved survival in Germinal Centre B-cell phenotype Michael Gilbertson Received Received
  222-P The addition of Rituximab to CODOX-M & IVAC in first Line therapy of poor risk Burkitt Lymphoma (IPI 3-5) yields an excellent outcome: a Phase 2 UK NCRI/LLR Trial (LLR 04058) andrew mcmillan Received Received
  225-P Prognostic impact of immunohistological profiling in primary CNS lymphoma Stephan Kreher Received Received
  226-P Addition of Rituximab to the Treatment of Newly Diagnosed Primary CNS Lymphoma is Associated with Improved Outcome: A French LOC Network study Emmanuel GYAN Received Received
  227-P BAM induction followed by autologous stem cell transplantation for patients with primary central nervous system lymphoma: a multicenter study from the Spanish group GEL-TAMO MIRIAM LÓPEZ-PARRA Received Received
  228-P High efficiency and tolerance of Temozolomide in relapse/refractory primary vitreo-retineal lymphoma: a multicentric study from the LOC network Sylvain Choquet Received Received
  229-P Temsirolimus for primary CNS lymphoma Stephan Kreher Received Received
  230-P Long-Term Outcome of 490 Patients with Early-Stage Extra-nodal Marginal Zone Lymphoma Sewit Teckie Received Received
  231-P Clinical Characteristics and Patterns of Care of Patients (pts) with Peripheral T-cell Lymphoma (PTCLs) according to age at time of diagnosis: A T-Cell Project snapshot. Monica Bellei Received Received
  232-P Characteristics and Patterns of Care of Patients (pts) =70 years with T-cell non-Hodgkin Lymphoma (TCL) in the United States (US) Chadi Nabhan Received Received
  233-P A large prospective multicenter study of peripheral T-cell lymphoma in Thailand: clinical, histopathology, treatment outcomes, and survival Jakrawadee Julamanee Received Received
  234-P A proposal of a new staging systemfor extranodal natural killer T-cell lymphoma, nasal-type: a multicenter study from Chinese Southwest Oncology Group (CSWOG) and Asia Lymphoma Study Group (ALSG) Tongyu Lin Received Received
  235-P A clinicopathological study of Lennert lymphoma and possible prognostic factors Daisuke Kurita Received Received
  236-P SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA IN THAILAND: CLINICAL OUTCOMES, TREATMENTS, AND PROGNOSTIC FACTORS Udomsak Bunworasate Received Received
  237-P Immunophenotypic heterogeneity of T-LGLL: clinical and biological implications Renato Zambello Received Received
  238-P Breast Implant Associated Anaplastic Large cell Lymphoma: a new distinct clinicopathologic entity. Camille Laurent Received Received
  239-P Molecular Heterogeneity of ALK-negative Anaplastic Large Cell Lymphoma Andrew Feldman Received Received
  243-P Polyethylene glycol conjugated asparaginase-CHOP in adult newly diagnosed extranodal NK/T-cell lymphoma: a multi-center prospective phase II study Wen Zheng Received Received
  244-P Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population Shunan Qi Received Received
  245-P Clinical Outcome of P-Gemox for Newly Diagnosed Stage III/IV or Relapsed/Refractory ENKTL HuiQiang Huang Received Received
  247-P The role of transplant in the treatment of Peripheral T-cell Lymphomas (PTCLs): an analysis from the T-Cell project database. Monica Bellei Received Received
  248-P Phase II study of SMILE chemotherapy for relapsed/refractory peripheral T-cell lymphoma Ritsuro Suzuki Received Received
  249-P Bendamustine treatment in refractory/relapsed T cell lymphomas: a retrospective multicenter study Emilie Reboursiere Received Received
  250-P The mTORC1 Inhibitor Everolimus Produces Tumor Responses in Patients with Relapsed T-cell Non-Hodgkin Lymphoma Thomas Witzig Received Received
  252-P Baseline metabolic tumor burden in DLBCL affects response to immuno-chemotherapy and patients outcome through influence of rituximab pharmacokinetics. A LYSA group study. Olivier Casasnovas Received Received
  254-P Role of bone marrow biopsy (BMB) in classic Hodgkin Lymphoma (cHL) staging in FDG-PET/CT era. benedetta puccini Received Received
  255-P Hodgkin Lymphoma: PET-CT or bone marrow biopsy? Zeinab Abou Yehia Received Received
  257-P PROGNOSTIC VALUE OF INTERIM FDG-PET/CT IN 100 DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP ACCORDING TO INTERPRETATION CRITERIA AND PRETHERAPEUTIC PROGNOSTIC FACTORS Caroline Faes Received Received
  258-P Blinded evaluation of the prognostic value of FDG-PET/CT after 2 cycles of RCHOP in DLBCL UK-NCRI study Mikhaeel George Received Received
  259-P No survival benefit associated with routine imaging for classical Hodgkin lymphoma in complete remission: A Danish-Swedish population-based study Tarec Christoffer El-Galaly Received Received
  261-P Biological Rational for Sequential Targeting of Bruton Tyrosine Kinase and Bcl2 to Overcome Cd40-induced BH3-mimetics Resistance in Mantle Cell Lymphoma David Chiron Received Received
  264-P Preclinical evaluation of the novel pleiotropic BCR kinase inhibitor IQS019 in in vitro and in vivo models of B lymphoid neoplasms Gael Roue Received Received
  266-P Transcriptomic profiling of response to PI3K inhibition by BKM120 in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) Micheal Coyle Received Received
  267-P Differential expression of PI3K isoforms/PTEN in follicular lymphoma and diffuse large B-cell lymphoma - therapeutic implications Lim Soon Thye Received Received
  268-P Inhibition of both PI3Ka and PI3Kd by Copanlisib is essential to attenuate both BCR-dependent and BCR-independent activation of NF&954;B and proliferation in DLBCL cells Juliane Paul Received Received
  269-P Pre-clinical lymphoma models show high sensitivity to the small molecule YK-4-279 Elaine Chung Received Received
  271-P The BET bromodomain inhibitor OTX015 (MK-8628) affects the expression of microRNAs involved in the pathogenesis of lymphoma: in vitro and in vivo evidence Afua Adjeiwaa Mensah Received Received
  272-P OTX015 (MK-8628) targets genes with high levels of promoter H3K4me3 involved in key signalling pathways in splenic marginal zone lymphoma and mantle cell lymphoma Chiara Tarantelli Received Received
  273-P Pixantrone has pre-clinical synergistic activity when combined with targeted agents in diffuse large B-cell lymphoma. Chiara Tarantelli Received Received
  274-P Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMGN529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models Angela Romanelli Received Received
  275-P A variant of obinutuzumab with abolished ADCC, ADCP and CDC is as efficient as rituximab in B cell depletion and antitumor activity Christian Klein Received Received
  277-P Targeting the MUC1-C oncoprotein is associated with downregulation of TIGAR and ROS-mediated cutaneous T-cell lymphoma cell death Salvia Jain Received Received
  278-P MYC and CHK1 Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models With Anti-Proteasomal Therapy Andrew Evens Received Received
  279-P Alisertib Exhibits Broad Activity And Selectively Synergizes With Romidepsin In Preclinical Models Of T-Cell Lymphoma Kelly Zullo Received Received
  280-P Interim Analysis of a Phase 1b Study Evaluating the Safety of GS-9820, a Second-Generation PI3Kd-Inhibitor, in Relapsed/Refractory Lymphoid Malignancies Arnon Kater Received Received
  282-P Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 Alliance) Patrick Johnston Received Received
  283-P Safety and clinical activity of Temsirolimus in combination with Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma Mathias Witzens-Harig Received Received
  286-P Phase I dose-escalation study of BI 836826 in patients (pts) with relapsed or refractory non-Hodgkin lymphoma (NHL) of B cell origin Janet Lightwood Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30 Fri 8:30-15:00
12:07
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image

INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

13th International Conference on Malignant Lymphoma

 

17-20 June 2015 Lugano
HELP LINE
Manage Orders
FAQs

You can now view the posters online!

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 16/06/2015 TO 17/06/2017
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.13icml.2015 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 15/06/2015
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster
PosterSessionOnline
Logo Draft
 
Logo Cert